GTR Test Accession:
Help
GTR000522366.2
Last updated in GTR:
2015-06-05
View version history
GTR000522366.2,
last updated:
2015-06-05
GTR000522366.1,
registered in GTR:
2015-05-20
Last annual review date for the lab: 2024-05-28
LinkOut
At a Glance
Test purpose:
Help
Diagnosis;
Risk Assessment
Conditions (21):
Help
Melanoma, cutaneous malignant, susceptibility to, 2;
Parathyroid carcinoma;
Pheochromocytoma
more...
Genes (32):
Help
Methods (1):
Help
Molecular Genetics - Sequence analysis of the entire coding region: Next-Generation (NGS)/Massively parallel sequencing (MPS)
Target population: Help
Not provided
Clinical validity:
Help
Not provided
Clinical utility:
Help
Not provided
Ordering Information
Offered by:
Help
Test Order Code:
Help
CAN05
Test development:
Help
Test developed by laboratory but exempt from FDA oversight (eg. NYS CLEP approved, offered within a hospital or clinic)
Pre-test genetic counseling required:
Help
Not provided
Post-test genetic counseling required:
Help
Not provided
Recommended fields not provided:
How to Order,
Specimen source,
Lab contact for this test,
Contact policy,
Informed consent required,
Pre-test genetic counseling required,
Post-test genetic counseling required,
Test strategy
Conditions
Help
Total conditions: 21
| Condition/Phenotype | Identifier |
|---|
Test Targets
Genes
Help
Total genes: 32
| Gene | Associated Condition | Germline or Somatic | Allele (Lab-provided) | Variant in NCBI |
|---|
Methodology
Total methods: 1
Method Category
Help
Test method
Help
Instrument *
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
* Instrument: Not provided
Clinical Information
Test purpose:
Help
Diagnosis;
Risk Assessment
Recommended fields not provided:
Clinical validity,
Clinical utility,
Target population,
What is the protocol for interpreting a variation as a VUS?,
Is research allowed on the sample after clinical testing is complete?,
Sample negative report,
Sample positive report
Technical Information
Availability:
Help
Tests performed
Entire test performed in-house
Entire test performed in-house
Analytical Validity:
Help
For diagnostic sequencing we require a minimal coverage of 30 high-quality, uniquely mapping non-duplicate reads over at least 97% of the target region. At this level, the lowest expected sensitivity is 99.998%. Pathogenic and unclear variants are resequenced using Sanger sequencing, providing a second, independent, confirmation.
Proficiency testing (PT):
Is proficiency testing performed for this test?
Help
No
No
Recommended fields not provided:
Test Confirmation,
Assay limitations,
Description of internal test validation method,
Citations for Analytical validity,
PT Provider,
Description of PT method,
Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review:
Help
Not provided
Additional Information
Reviews:
Clinical resources:
Molecular resources:
Consumer resources:
IMPORTANT NOTE:
NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading.
NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice.
Patients and consumers
with specific questions about a genetic test should contact a health care provider or a genetics professional.